Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Switch To ViiV's Two-Drug Dovato Keeps HIV Suppressed

Executive Summary

Top-line results from the Phase III TANGO study suggests that switching to ViiV’s two-drug Dovato from a three-drug regimen does not affect the efficacy of treatment.

You may also be interested in...



Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta

The latest drug development news and highlights from our US FDA Performance Tracker.

ViiV Says Latest Data Back Two-Drug Approach, Plans Year-End Fostemsavir Filing

ViiV Healthcare research head tells Scrip she expects Dovato’s latest data presentation should boost the two-drug regimen’s uptake, and that the AIDS-fighter plans a US FDA filing of its investigational candidate fostemsavir before end-2019 following good Phase III BRIGHTE results.

GSK Q2 Preview: Focus On PARP And HIV Pill

Analysts are waiting to see how the drugs giant intends to drive growth for new products, with a particular interest in the prospects for the PARP inhibitor Zejula and the single-pill, two-drug HIV therapy Dovato.

Related Content

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel